Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Research & Development for 6 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 29.25% year-over-year to $7.9 million, compared with a TTM value of $31.2 million through Dec 2025, up 21.93%, and an annual FY2025 reading of $31.2 million, up 21.93% over the prior year.
  • Research & Development was $7.9 million for Q4 2025 at Xeris Biopharma Holdings, up from $7.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.1 million in Q4 2021 and bottomed at $3.7 million in Q2 2022.
  • Average Research & Development over 5 years is $6.3 million, with a median of $6.1 million recorded in 2022.
  • The sharpest move saw Research & Development plummeted 50.85% in 2022, then skyrocketed 63.72% in 2023.
  • Year by year, Research & Development stood at $10.1 million in 2021, then tumbled by 50.85% to $5.0 million in 2022, then increased by 28.8% to $6.4 million in 2023, then fell by 4.54% to $6.1 million in 2024, then grew by 29.25% to $7.9 million in 2025.
  • Business Quant data shows Research & Development for XERS at $7.9 million in Q4 2025, $7.5 million in Q3 2025, and $8.1 million in Q2 2025.